China Universal Asset Management Company’s Tourmaline Bio TRML Stock Holding History

China Universal Asset Management Company’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,503	Closed	-$215K	–	532
2025 Q3	$215K	Sell	4,503 -656	-13%	-$18.2K	0.02%	329
2025 Q2	$82.5K	Buy	5,159 +16	+0.3%	+$259	0.01%	381
2025 Q1	$78.2K	Sell	5,143 -294	-5%	-$4.71K	0.01%	378
2024 Q4	$110K	Buy	5,437 +505	+10%	+$12.7K	0.01%	379
2024 Q3	$127K	Buy	4,932 +1,920	+64%	+$32K	0.01%	337
2024 Q2	$38.7K	Sell	3,012 -1,927	-39%	-$31K	0.01%	372
2024 Q1	$113K	Buy	4,939 +2,582	+110%	+$91K	0.01%	361
2023 Q4	$61.7K	Buy	+2,357	New	+$47.2K	0.01%	345
2022 Q4	–	Sell	-39	Closed	-$1K	–	467
2022 Q3	$1K	Buy	+39	New	+$1.42K	﹤0.01%	417

China Universal Asset Management Company's TRML Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 4,503 shares — an estimated $215K sold.

China Universal Asset Management Company first reported a position in TRML in Q3 2022 and held it in 9 quarters. The position peaked at $215K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

China Universal Asset Management Company reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
China Universal Asset Management Company sold 4,503 Tourmaline Bio shares in Q4 2025, an estimated $215K.
China Universal Asset Management Company first reported a position in Tourmaline Bio in Q3 2022 and held it in 9 quarters.
China Universal Asset Management Company's Tourmaline Bio position peaked at $215K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.